ClinicalTrials.gg

Program

ropanicant

Also written as “Ropanicant” and “SUVN-911”.

Its studies are mostly in Depressive Disorder, Major, led by Suven Life Sciences.

Furthest: phase 2, since Nov 6, 20234 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Suven Life Sciences40 open or runningphase 2since Nov 6, 2023May 11, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 11, 2017First study: phase 1 study in Depressive Disorder, MajorFirst studyNCT03155503 · 64 enrolled · United States
  2. May 28, 2018Phase 1 study in Depressive Disorder, MajorNCT03551288 · 28 enrolled · United States
  3. Nov 6, 2023Phase 2 study in Depressive Disorder, MajorNCT06126497 · 41 enrolled · United States
  4. Feb 18, 2025Phase 2 study in Depressive Disorder, MajorNCT06836063 · 214 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06836063Depressive Disorder, Major · United States2CompletedFeb 23, 2026214
NCT06126497Depressive Disorder, Major · United States2CompletedJul 19, 202441
NCT03551288Depressive Disorder, Major · United States1CompletedJul 10, 201828
NCT03155503Depressive Disorder, Major · United States1CompletedMar 7, 201864

How it is read

Names in the registry

  • “Ropanicant”, 2 entries
  • “SUVN-911”, 2 entries

Codes read as this program: SUVN911.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
ropanicant (Suven Life Sciences): development program | ClinicalTrials.gg